Latest Content

Trump is expected to pick White House aide Dr. Heidi Overton to lead the FDA, pending Senate confirmation, as the agency works to rebuild industry trust.

IAG Cargo has added a Kuala Lumpur station to its Constant Climate network, its 13th in Asia-Pacific, as regional biologics and personalized medicine demand accelerates.

EVERSANA's Vikram Anand breaks down FDA data on complete response letters, showing how gaps in pharmacovigilance and safety readiness, not manufacturing alone, drive costly delays in drug commercialization.

Separating the combination MMR shot into three vaccines would not just change how children are immunized. It would require building three new supply chains from a licensing base that does not yet exist.

Episode 2 of Supply Chain Signal breaks down the July 31 and September 29 Section 232 deadlines and the proposed generics tariff plan, and what they mean for reshoring.

DSCSA verifies package movement, but resilience requires visibility into capacity, quality and sourcing risk.

Patient Advocate Foundation's Amy Niles on faster CMS prior authorization rules, Medicaid work requirements and what shrinking coverage means for patients.

In this week's Pharma Pulse, Eli Lilly sues companies over black-market retatrutide sales, Bristol Myers Squibb commits $2.3 billion to a new Houston manufacturing campus, and FDA opens an assessment of small dispensers' DSCSA tracing capabilities.

Ed Schoonveld examines how AI is reshaping drug pricing and access, from payer decisions to prescribing, and what it means for new drug treatments.

Adam Colborn explains why affordability and access aren't the same thing for TrumpRx, and how pharmacy participation gaps can leave patients stuck.

Colborn breaks down why most AMCP members don't see TrumpRx as the lowest price option, and what that means for MFN pricing claims.

DTP programs are outpacing regulatory guidance. Chander Viswanathan and Shannon Wiley, JD make the case for compliance-by-design infrastructure over reactive fixes.

Bristol Myers Squibb will build a $2.3 billion modular manufacturing campus in Houston, part of a $40 billion five-year US investment pledge.